Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma

DA Braun, Z Bakouny, L Hirsch, R Flippot… - Nature reviews Clinical …, 2021 - nature.com
The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …

Targeting CD39 in cancer

AK Moesta, XY Li, MJ Smyth - Nature Reviews Immunology, 2020 - nature.com
The ATP–adenosine pathway functions as a key modulator of innate and adaptive immunity
within the tumour microenvironment. Consequently, multiple clinical strategies are being …

Tumor microenvironment dynamics in clear-cell renal cell carcinoma

L Vuong, RR Kotecha, MH Voss, AA Hakimi - Cancer discovery, 2019 - AACR
Renal cell carcinoma stands out as one of the most immune-infiltrated tumors in pan-cancer
comparisons. Features of the tumor microenvironment heavily affect disease biology and …

Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan–kynurenine–aryl hydrocarbon axis

BW Labadie, R Bao, JJ Luke - Clinical Cancer Research, 2019 - AACR
Significant progress has been made in cancer immunotherapy with checkpoint inhibitors
targeting programmed cell death protein 1 (PD-1)–programmed death-ligand 1 signaling …

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

AJ Muller, MG Manfredi, Y Zakharia… - Seminars in …, 2019 - Springer
With immunotherapy enjoying a rapid resurgence based on the achievement of durable
remissions in some patients with agents that derepress immune function, commonly referred …

Applications of metabolomics to study cancer metabolism

AK Kaushik, RJ DeBerardinis - … et Biophysica Acta (BBA)-Reviews on …, 2018 - Elsevier
Reprogrammed metabolism supports tumor growth and provides a potential source of
therapeutic targets and disease biomarkers. Mass spectrometry-based metabolomics has …

[HTML][HTML] CD39–A bright target for cancer immunotherapy

S Guo, F Han, W Zhu - Biomedicine & Pharmacotherapy, 2022 - Elsevier
The ATP-adenosine pathway functions as a key modulator of innate and adaptive immunity
within the tumor microenvironment, and cancer immune evasion largely involves the …

Circulating immune bioenergetic, metabolic, and genetic signatures predict melanoma patients' response to anti–pd-1 immune checkpoint blockade

PL Triozzi, ER Stirling, Q Song, B Westwood… - Clinical Cancer …, 2022 - AACR
Purpose: Immunotherapy with checkpoint inhibitors is improving the outcomes of several
cancers. However, only a subset of patients respond. Therefore, predictive biomarkers are …

Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability–high/mismatch …

A Hollebecque, HC Chung, MJ De Miguel… - Clinical Cancer …, 2021 - AACR
Purpose: Immune checkpoint inhibitors show high response rates and durable clinical
benefit in microsatellite instability–high/mismatch repair–deficient (MSI-H/dMMR) tumors …

Emerging applications of metabolomics in clinical pharmacology

H Pang, W Jia, Z Hu - Clinical Pharmacology & Therapeutics, 2019 - Wiley Online Library
Metabolic disturbances have been associated with many human diseases, including cancer,
diabetes, and cardiovascular disease. Metabolomics, a rapidly growing member of the …